Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Stoke Therapeutics, Inc.NASDAQ: STOK
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $6.23M fell 96.1% year over year, behind the -83.2% change in trailing-twelve-month revenue. Sequentially, it rose 344.3% from the prior quarter. Over 3 fiscal years it compounded at +145.9% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 9 analysts of $35.47M (-80.8%) for the fiscal year ending Dec 2026, a slowdown from the +404.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.23M+344.3% QoQ
- Last fiscal yearDec 2025
- $184.42M+404.5% YoY
- LTMMar 2026
- $32.08M-83.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -96.1% | -64.6% | +31.5 pp |
| 1 year | +404.5% | -80.8% | -485.3 pp |
| 3-year CAGR | +145.9% | -9.6% | -155.5 pp |
| 5-year CAGR | +27.1% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 184.42M USD
- Year-over-year change
- +404.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 184.42M | +404.5% |
| FY2024 | 2024-12-31 | 36.56M | +316.3% |
| FY2023 | 2023-12-31 | 8.78M | -29.2% |
| FY2022 | 2022-12-31 | 12.41M | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -83.2% is the lowest of 5, against a peer median of -14.9%.
- Over three fiscal years its annual growth of +145.9% compares with a peer median of +31.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $959.76M USD | -0.7% | +17.1% | |
| LTM Jun 2026 | $156.04M USD | +158.9% | +31.9% | |
| LTM Mar 2026 | $71.8M USD | -31.6% | +127.1% | |
| LTM Mar 2026 | $32.08M USD | -83.2% | +145.9% | |
| LTM Mar 2026 | €13.44M EUR | -29.2% | +62.0% | |
| LTM Mar 2026 | $921.49K USD | — | -68.4% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding STOK) | — | -14.9% | +31.9% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| Selling, General & Admin | 31.9M | 38.92M | 41.32M | 48.79M | 67.09M |
| Operating Expenses | 86.07M | 116.76M | 123.55M | 137.93M | 205.01M |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| EBITDA | (84.83M) | (99.52M) | (102.23M) | (86.8M) | (5.12M) |
| EBITDA Margin | — | -802.3% | -1164.4% | -237.5% | -2.8% |
| Operating Income | (86.07M) | (104.36M) | (114.77M) | (101.37M) | (20.59M) |
| Operating Margin | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Interest Income | 120K | 3.12M | 9.91M | 12.64M | 13.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 9K |
| Other Income / Expenses | 260K | 3.29M | 10.07M | 12.39M | 13.71M |
| Income Before Tax | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Pre-Tax Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Net Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (Basic) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| EPS (Diluted) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| Weighted Avg Shares | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Weighted Avg Shares (Diluted) | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.